Cart

This article PDF is available for purchase only. PDFs are free for members! Become a member and save today

Remove item Thumbnail image Product Price Quantity Subtotal
× Placeholder Beneficial Effects of the Sigma-1 Agonist Fluvoxamine for Tardive Dyskinesia in Patients With Postpsychotic Depressive Disorder of Schizophrenia: Report of 5 Cases PDF $40.00
$40.00
× Placeholder Number Needed to Treat to Harm for Discontinuation Due to Adverse Events in the Treatment of Bipolar Depression, Major Depressive Disorder, and Generalized Anxiety Disorder With Atypical Antipsychotics PDF $40.00
$40.00
× Placeholder A Positive Association Between Homeostasis Model Assessment of Insulin Resistance Score and the Trp64Arg Polymorphism of the β3-Adrenergic Receptor Gene in Schizophrenia Patients in Taiwan PDF $40.00
$40.00
× Placeholder The Association Between Borderline Personality Disorder and Chronic Medical Illnesses, Poor Health-Related Lifestyle Choices, and Costly Forms of Health Care Utilization PDF $40.00
$40.00
× Placeholder Quality of Life Following Remission of Mental Disorders: Findings From the National Epidemiologic Survey on Alcohol and Related Conditions PDF $40.00
$40.00
× Placeholder Is Virtual Reality Effective to Motivate and Raise Interest in Phobic Children Toward Therapy? A Clinical Trial Study of In Vivo With In Virtuo Versus In Vivo Only Treatment Exposure PDF $40.00
$40.00
× Placeholder Assertive Community Treatment as Part of Integrated Care Versus Standard Care: A 12-Month Trial in Patients With First- and Multiple-Episode Schizophrenia Spectrum Disorders Treated With Quetiapine Immediate Release (ACCESS Trial) PDF $40.00
$40.00

Instead of purchasing individual articles, subscribe to our membership plan and get unlimited access to all article PDFs from both of our journals.


Join Now

Cart totals

Subtotal $280.00
Total $280.00